Articles tagged with Active Mutants
Researchers have discovered that a rare genetic mutation delays Alzheimer's disease by suppressing inflammatory signaling in the brain. The study found that inhibiting this pathway with a drug-like inhibitor replicated key protective effects of the mutation in a preclinical model.
The Lung Cancer Research Foundation and Israel Cancer Research Fund are partnering to test an innovative new treatment for lung cancer. The project aims to explore the effects of a drug that targets IGF2BP1, a protein involved in cancer cell growth.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
Researchers found that hepatitis E virus (HEV) mutations made treatment with individual drugs less effective, highlighting the need for combination therapies. The study's findings also provide insights into the evolutionary dynamics of HEV, paving the way for next-generation antiviral treatments.
Researchers found that genetically modified tobacco mutants, impaired in their defenses, outperformed wild-type plants in years with low herbivore pressure. The mutants' prioritization of growth and reproduction over defense allowed them to thrive in environments with limited insect damage.
Researchers found significant decreases in the levels of KRAS, RHOA, RAC1, and CDC42 after PCAI treatment, implicating their role in cancer progression and metastasis. These findings support the potential of PCAIs as potent agents for developing new anticancer therapeutics.
Researchers have uncovered the mechanism behind severe cases of G6PD deficiency, identifying a chain of amino acids that warps the shape of the condition's namesake protein. This breakthrough could pave the way for new treatments and therapeutics for Class I patients, who currently rely on blood transfusions.